A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures

Brief description of study

In this research study, the sponsor is testing two (2) different doses of EQU-001 for safety and for the ability to reduce seizures. The safety of this study drug has already been tested in a small number of healthy volunteers for up to 14 days at doses up to 120 mg per day, twice the highest dose tested in this study. Safety has also been tested at low doses (up to 20 mg) for several months in small number of patients with epilepsy (approximately 20) in a trial that is now ongoing. The EQU-001 capsule is considered to be experimental or investigational because it has not been approved by the U.S. Food and Drug Administration (FDA) or by the European Medicines Agency (EMA) for the treatment of seizures. However, the drug that is in the EQU-001 capsule has been approved for use in humans for the treatment of parasitic infections. To treat parasites, the drug is given only in one or two doses, rather than every day. This will be the second study of the EQU-001 capsule taken daily in patients with epilepsy.

Interested participants should reach out to CECResearchStudyInfo@nyulangone.org.

Clinical Study Identifier: s22-00777
ClinicalTrials.gov Identifier: NCT05473442

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.